HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing ctl responses and protective immunity

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1537-1545

  Nguyen Hoai, Tam ^a   Kobelt, Dennis ^a   Hohn, Oliver ^b   Vu, Minh D ^a   Schlag, Peter M ^a   Dörken, Bernd ^a   Norley, Steven ^b   Lipp, Martin ^a   Walther, Wolfgang ^a   Pezzutto, Antonio ^a   Westermann, Jörg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

CTL response; DNA vaccination; Gene gun; HER2 neu; Jet injector

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POLARITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE DELIVERY SYSTEM; GENE GUN; GENE GUN IMMUNIZATION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INTERMETHOD COMPARISON; JET INJECTOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; TH1 CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR MODEL;

EID: 84886945450     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22563     Document Type: Article

References (60)

1. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18:927-74; PMID:10837079; http://dx.doi.org/10.1146/annurev.immunol.18.1.927.
2. Choo AY, Choo DK, Kim JJ, Weiner DB. DNA vaccination in immunotherapy of cancer. Cancer Treat Res 2005; 123:137-56; PMID:16211869; http://dx.doi.org/10.1007/0-387-27545-2_6.
3. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004; 114:1241-4; PMID:15520855.
4. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108-20; PMID:18219306; http://dx.doi.org/10.1038/nrc2326.
5. Prud'homme GJ. DNA vaccination against tumors. J Gene Med 2005; 7:3-17; PMID:15538731; http://dx.doi.org/10.1002/jgm.669.
6. Iezzi M, Quaglino E, Amici A, Lollini PL, Forni G, Cavallo F. DNA vaccination against oncoantigens: A promise. Oncoimmunology 2012; 1:316- 25; PMID:22737607; http://dx.doi.org/10.4161/onci.19127.
7. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90:175- 213; PMID:16730264; http://dx.doi.org/10.1016/S0065-2776(06)90005-4.
8. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003; 21:649-58; PMID:12531334; http://dx.doi.org/10.1016/S0264-410X(02)00574-1.
9. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLRbased immune adjuvants. Vaccine 2011; 29:3341-55; PMID:20713100; http://dx.doi.org/10.1016/j.vaccine.2010.08.002.
10. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 2001; 19:2647-56; PMID:11257404; http://dx.doi.org/10.1016/S0264-410X(00)00495-3.
11. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007; 25:3731-41; PMID:17350735; http://dx.doi.org/10.1016/j.vaccine.2007.01.120.
12. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID:1690918; http://dx.doi.org/10.1126/science.1690918.
13. Frelin L, Brass A, Ahlén G, Brenndörfer ED, Chen M, Sällberg M. Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans? Drug News Perspect 2010; 23:647-53; PMID:21180650; http://dx.doi.org/10.1358/dnp.2010.23.10.1513492.
14. Hutnick NA, Myles DJF, Bian CB, Muthumani K, Weiner DB. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol 2011; 1:233-40; PMID:22440782;
15. Lin F, Shen X, McCoy JR, Mendoza JM, Yan J, Kemmerrer SV, et al. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 2011; 29:6771-80; PMID:21199706; http://dx.doi.org/10.1016/j.vaccine.2010.12.057.
16. Vahlsing HL, Yankauckas MA, Sawdey M, Gromkowski SH, Manthorpe M. Immunization with plasmid DNA using a pneumatic gun. J Immunol Methods 1994; 175:11-22; PMID:7930633; http://dx.doi.org/10.1016/0022-1759(94)90327-1.
17. Haensler J, Verdelet C, Sanchez V, Girerd-Chambaz Y, Bonnin A, Trannoy E, et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999; 17:628-38; PMID:10067667; http://dx.doi.org/10.1016/S0264-410X(98)00242-4.
18. Sawamura D, Ina S, Itai K, Meng X, Kon A, Tamai K, et al. In vivo gene introduction into keratinocytes using jet injection. Gene Ther 1999; 6:1785- 7; PMID:10516730; http://dx.doi.org/10.1038/sj.gt.3301002.
19. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TNM, et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11:899-904; PMID:15965482; http://dx.doi.org/10.1038/nm1264.
20. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2:1122-8; PMID:8837611; http://dx.doi.org/10.1038/nm1096-1122.
21. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188:1075-82; PMID:9743526; http://dx.doi.org/10.1084/jem.188.6.1075.
22. Romani N, Holzmann S, Tripp CH, Koch F, Stoitzner P. Langerhans cells - dendritic cells of the epidermis. APMIS 2003; 111:725-40; PMID:12974775; http://dx.doi.org/10.1034/j.1600-0463.2003.11107805.x.
23. Bauer J, Bahmer FA, Wörl J, Neuhuber W, Schuler G, Fartasch M. A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical disector method and the confocal laser scanning microscope. J Invest Dermatol 2001; 116:313-8; PMID:11180009; http://dx.doi.org/10.1046/j.1523-1747.2001.01247.x.
24. Bergstresser PR, Fletcher CR, Streilein JW. Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J Invest Dermatol 1980; 74:77-80; PMID:6985948; http://dx.doi.org/10.1111/1523-1747.ep12519909.
25. Lenz A, Heine M, Schuler G, Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 1993; 92:2587- 96; PMID:8254016.
26. Walther W, Stein U, Fichtner I, Malcherek L, Lemm M, Schlag PM. Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology. Gene Ther 2001; 8:173-80; PMID:11313788; http://dx.doi.org/10.1038/sj.gt.3301350.
27. Walther W, Stein U, Lage H. Jet-injection of short hairpin RNA-encoding vectors into tumor cells. Methods Mol Biol 2010; 629:123-39; PMID:20387147; http://dx.doi.org/10.1007/978-1-60761-657-3_9.
28. Walther W, Stein U, Fichtner I, Kobelt D, Aumann J, Arlt F, et al. Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma. Mol Ther 2005; 12:1176- 84; PMID:16202659; http://dx.doi.org/10.1016/j.ymthe.2005.07.700.
29. Walther W, Stein U, Fichtner I, Schlag PM. Low-volume jet injection for efficient nonviral in vivo gene transfer. Mol Biotechnol 2004; 28:121-8; PMID:15477651; http://dx.doi.org/10.1385/MB:28:2:121.
30. Walther W, Siegel R, Kobelt D, Knösel T, Dietel M, Bembenek A, et al. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res 2008; 14:7545-53; PMID:19010873; http://dx.doi.org/10.1158/1078-0432.CCR-08-0412.
31. Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22:6570-8; PMID:14528282; http://dx.doi.org/10.1038/sj.onc.1206779.
32. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, et al. Breast cancer vaccines: a clinical reality or fairy tale?. Ann Oncol 2006; 17:750-62; PMID:16293674; http://dx.doi.org/10.1093/annonc/mdj083.
33. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010; 2:213-26; PMID:20635929; http://dx.doi.org/10.2217/imt.09.89.
34. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14:797-803; PMID:18245541; http://dx.doi.org/10.1158/1078-0432.CCR-07-1448.
35. Nguyen-Hoai T, Baldenhofer G, Ahmed MS, Pham-Duc M, Gries M, Lipp M, et al. CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model. J Gene Med 2012; 14:128-37; PMID:22228591; http://dx.doi.org/10.1002/jgm.1651.
36. Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed MS, Pham-Duc M, Vu MD, Lipp M, et al. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Ther 2012; 19:69-76; PMID:21997231; http://dx.doi.org/10.1038/cgt.2011.69.
37. Smorlesi A, Papalini F, Amici A, Orlando F, Pierpaoli S, Mancini C, et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 2006; 24:1766-75; PMID:16288939; http://dx.doi.org/10.1016/j.vaccine.2005.10.022.
38. Lindencrona JA, Preiss S, Kammertoens T, Schüler T, Piechocki M, Wei WZ, et al. CD4+ T cellmediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004; 109:259- 64; PMID:14750178; http://dx.doi.org/10.1002/ijc.11654.
39. Greenberg PD, Cheever MA, Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med 1981; 154:952-63; PMID:6974221; http://dx.doi.org/10.1084/jem.154.3.952.
40. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000; 13:265-76; PMID:10981969; http://dx.doi.org/10.1016/S1074-7613(00)00026-1.
41. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003; 21:4036-42; PMID:12922140; http://dx.doi.org/10.1016/S0264-410X(03)00275-5.
42. Raviprakash K, Porter KR. Needle-free injection of DNA vaccines: a brief overview and methodology. Methods Mol Med 2006; 127:83-9; PMID:16988448.
43. Janouskova O, Nellessen T, Stokrova J, Jinoch P, Smahel M. Delivery of recombinant adeno-associated virus by jet injection. Int J Mol Med 2003; 12:687-91; PMID:14532994
44. Kanazawa T, Takashima Y, Tamura T, Tsuchiya M, Shibata Y, Udagawa H, et al. Local gene expression and immune responses of vaginal DNA vaccination using a needle-free injector. Int J Pharm 2010; 396:11- 6; PMID:20621704; http://dx.doi.org/10.1016/j.ijpharm.2010.05.040.
45. Imoto J, Konishi E. Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model. Viral Immunol 2005; 18:205-12; PMID:15802965; http://dx.doi.org/10.1089/vim.2005.18.205.
46. Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, et al. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposablesyringe jet injector. Vaccine 2011; 29:9544-50; PMID:21986218; http://dx.doi.org/10.1016/j.vaccine.2011.09.097.
47. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006; 5:543-8; PMID:16816837.
48. Ren S, Li M, Smith JM, De Tolla LJ, Furth PA. Lowvolume jet injection for intradermal immunization in rabbits. BMC Biotechnol 2002; PMID:12028591; 2:10.http://dx.doi.org/10.1186/1472-6750-2-10.
49. Schramm-Baxter J, Mitragotri S. Needle-free jet injections: dependence of jet penetration and dispersion in the skin on jet power. J Control Release 2004; 97:527- 35; PMID:15212884; http://dx.doi.org/10.1016/j.jconrel.2004.04.006.
50. Stoecklinger A, Grieshuber I, Scheiblhofer S, Weiss R, Ritter U, Kissenpfennig A, et al. Epidermal langerhans cells are dispensable for humoral and cell-mediated immunity elicited by gene gun immunization. J Immunol 2007; 179:886-93; PMID:17617579.
51. Stoecklinger A, Eticha TD, Mesdaghi M, Kissenpfennig A, Malissen B, Thalhamer J, et al. Langerin+ dermal dendritic cells are critical for CD8+ T cell activation and IgH γ-1 class switching in response to gene gun vaccines. J Immunol 2011; 186:1377-83; PMID:21187444; http://dx.doi.org/10.4049/jimmunol.1002557.
52. Moser M. Dendritic cells in immunity and tolerancedo they display opposite functions? Immunity 2003; 19:5-8; PMID:12871634; http://dx.doi.org/10.1016/S1074-7613(03)00182-1.
53. Kalinski P, Moser M. Consensual immunity: successdriven development of T-helper-1 and T-helper-2 responses. Nat Rev Immunol 2005; 5:251-60; PMID:15738955; http://dx.doi.org/10.1038/nri1569.
54. Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 2010; 22:144-54; PMID:20413326; http://dx.doi.org/10.1016/j.smim.2010.03.004.
55. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004; 95:697-703; PMID:15471553; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03248.x.
56. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011; 23:146-52; PMID:20970973; http://dx.doi.org/10.1016/j.coi.2010.09.008.
57. Chen Y, Webster RG, Woodland DL. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J Immunol 1998; 160:2425- 32; PMID:9498786.
58. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003; 111:1161- 70; PMID:12697735.
59. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, et al. Peptides derived from a wildtype murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159:1336-43; PMID:9233630.
60. Piechocki MP, Pilon SA, Wei WZ. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 2002; 259:33-42; PMID:11730839; http://dx.doi.org/10.1016/S0022-1759(01)00487-2.